Posted: 14 December
Starpharma announces preliminary AZD0466 clinical trial results from the ongoing Phase 1/2 trial in patients with advanced relapsed/refractory leukemia (NCT04865419), presented by Starpharma’s partner AstraZeneca at the 2022 American Society of Hematology (ASH) Annual Meeting.
The clinical data reported show that AZD0466 has been well tolerated, with no DLTs reported to date and no discontinuations due to treatment-related adverse events. Five dose escalations have already been successfully completed, with further dose escalations underway. This Phase 1/2 trial in relapsed/refractory leukemia patients continues to enroll at 17 sites across the United States, Europe, Asia and Australia, with more than 30 additional sites planned.
Starpharma’s dendrimer drug delivery technology, known as DEP, is used to enhance the therapeutic properties of drugs to improve solubility, efficacy, pharmacokinetics, targeting, and reduce certain toxicities. Starpharma has developed three clinical stage products using the DEP technology, which is also the subject of multiple partnerships with leading pharmaceutical companies, including AstraZeneca, Merck & Co., Inc., Genentech, and Chase Sun.
